• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.循环核小体、HMGB1 和 sRAGE 与前列腺癌诊断的相关性。
In Vivo. 2021 Jul-Aug;35(4):2207-2212. doi: 10.21873/invivo.12492.
2
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.晚期胰腺癌化疗患者循环核小体和免疫原性细胞死亡标志物 HMGB1、sRAGE 和 DNAse。
Int J Cancer. 2013 Dec 1;133(11):2619-30. doi: 10.1002/ijc.28294. Epub 2013 Aug 9.
3
[The Value of Serum HMGB1 and sRAGE in the Diagnosis, Efficacy Monitoring and Prognosis of Newly Diagnosed Multiple Myeloma].[血清高迁移率族蛋白B1和可溶性晚期糖基化终末产物受体在新诊断多发性骨髓瘤诊断、疗效监测及预后中的价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Apr;30(2):493-500. doi: 10.19746/j.cnki.issn.1009-2137.2022.02.028.
4
Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy.循环核小体和免疫原性细胞死亡的生物标志物作为接受细胞毒性治疗的癌症患者的预测和预后标志物。
Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S217-24. doi: 10.1517/14712598.2012.689280.
5
Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies.免疫原性生物标志物HMGB1和可溶性晚期糖基化终末产物受体是卵巢恶性肿瘤的潜在诊断工具。
Cancers (Basel). 2023 Oct 20;15(20):5081. doi: 10.3390/cancers15205081.
6
Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients.原发性抗磷脂抗体综合征患者血浆中高迁移率族蛋白盒1及晚期糖基化终产物可溶性受体水平
PLoS One. 2017 May 30;12(5):e0178404. doi: 10.1371/journal.pone.0178404. eCollection 2017.
7
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.新辅助化疗期间乳腺癌患者循环免疫原性细胞死亡生物标志物HMGB1和RAGE
Tumour Biol. 2013 Feb;34(1):81-90. doi: 10.1007/s13277-012-0513-1. Epub 2012 Sep 15.
8
Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis.急性胰腺炎患者血浆中高迁移率族蛋白1、晚期糖基化终产物可溶性受体及循环DNA的浓度
Pancreatology. 2009;9(4):383-91. doi: 10.1159/000181172. Epub 2009 May 19.
9
Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.急性肝衰竭患者中晚期糖基化终产物可溶性受体及晚期糖基化终产物受体配体的循环水平。
Liver Transpl. 2015 Jun;21(6):847-54. doi: 10.1002/lt.24129.
10
High-mobility group box 1 protein, receptor for advanced glycation end products and nucleosomes increases after marathon.马拉松赛后高迁移率族蛋白B1、晚期糖基化终末产物受体和核小体增加。
Front Physiol. 2023 Feb 14;14:1118127. doi: 10.3389/fphys.2023.1118127. eCollection 2023.

引用本文的文献

1
Quantification of H3.1-nucleosomes using a chemiluminescent immunoassay: A reliable method for neutrophil extracellular trap detection.使用化学发光免疫测定法对H3.1核小体进行定量:一种检测中性粒细胞胞外诱捕网的可靠方法。
PLoS One. 2025 Aug 6;20(8):e0329352. doi: 10.1371/journal.pone.0329352. eCollection 2025.
2
DNA-Binding Proteins and Passenger Proteins in Plasma DNA-Protein Complexes: Imprint of Parental Cells or Key Mediators of Carcinogenesis Processes?血浆 DNA-蛋白质复合物中的 DNA 结合蛋白和载脂蛋白:亲代细胞的印记还是致癌过程的关键介质?
Int J Mol Sci. 2024 May 9;25(10):5165. doi: 10.3390/ijms25105165.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
What chance do we have to decrease prostate cancer overdiagnosis and overtreatment? A narrative review.我们有多大机会减少前列腺癌的过度诊断和过度治疗?一项叙述性综述。
Acta Biomed. 2019 Dec 23;90(4):423-426. doi: 10.23750/abm.v90i4.9070.
3
Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer.循环核小体及核小体修饰作为癌症生物标志物
Cancers (Basel). 2017 Jan 8;9(1):5. doi: 10.3390/cancers9010005.
4
Clarifying the PSA grey zone: The management of patients with a borderline PSA.明确前列腺特异性抗原(PSA)灰色地带:PSA临界值患者的管理
Int J Clin Pract. 2016 Nov;70(11):950-959. doi: 10.1111/ijcp.12883. Epub 2016 Sep 27.
5
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.PRIAS 研究中的十年主动监测:更新和评估推荐转为主动治疗的标准。
Eur Urol. 2016 Dec;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007. Epub 2016 Jun 19.
6
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.循环 HMGB1 和 RAGE 作为恶性和自身免疫性疾病的临床生物标志物。
Diagnostics (Basel). 2015 Jun 16;5(2):219-53. doi: 10.3390/diagnostics5020219.
7
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.2014年国际泌尿病理学会(ISUP)前列腺癌Gleason分级共识会议:分级模式的定义及新分级系统的建议
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
8
How cell death shapes cancer.细胞死亡如何塑造癌症。
Cell Death Dis. 2015 Mar 5;6(3):e1675. doi: 10.1038/cddis.2015.20.
9
Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.RAGE 和 HMGB1 的共表达与前列腺癌的肿瘤进展和患者预后不良相关。
Am J Cancer Res. 2014 Jul 16;4(4):369-77. eCollection 2014.
10
Overdiagnosis and overtreatment of prostate cancer.前列腺癌的过度诊断与过度治疗。
Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9.

循环核小体、HMGB1 和 sRAGE 与前列腺癌诊断的相关性。

Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.

机构信息

Department of Clinical Pathology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal;

Department of Laboratory Medicine, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

出版信息

In Vivo. 2021 Jul-Aug;35(4):2207-2212. doi: 10.21873/invivo.12492.

DOI:10.21873/invivo.12492
PMID:34182498
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8286487/
Abstract

BACKGROUND/AIM: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa.

PATIENTS AND METHODS

A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays.

RESULTS

There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180).

CONCLUSION

In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.

摘要

背景/目的:逃避细胞死亡发生在前列腺癌(PCa)中。我们验证了细胞死亡标志物的血清水平是否在 PCa 中有诊断价值。

患者和方法

共纳入 233 名计划进行前列腺活检的男性[前列腺特异性抗原(PSA)水平:2-10ng/ml]。通过酶免疫分析法分析血清核小体、含有 H3 组蛋白(H3)的核小体、高迁移率族蛋白 B1(HMGB1)和可溶性晚期糖基化终产物受体(sRAGE)。

结果

有或没有 PCa 或临床显著 PCa(csPCa)的患者之间核小体、H3 和 sRAGE 水平无差异(p>0.05)。HMGB1 在 PCa 患者中的水平较低(p=0.023),是 PCa 的预测因子(p=0.047),但不是 csPCa 的预测因子(p=0.180)。

结论

在 PSA 水平在 2-10ng/ml 之间的临界患者中,HMGB1 对整体 PCa 检测具有一定的诊断价值,但对 csPCa 没有预测价值。核小体、H3 和 sRAGE 不能区分 PCa 或 csPCa 与对照组。